Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse

1 hour ago 1

MarketBeat

Sat, July 11, 2026 astatine 4:02 PM CDT 7 min read

Key Points

Interested successful Vertex Pharmaceuticals Incorporated? Here are 5 stocks we similar better.
Vertex Pharmaceuticals agreed to bargain Crinetics Pharmaceuticals for $85 per stock successful cash, valuing the woody astatine astir $10 billion equity worth ($8.8 cardinal nett of cash). Vertex says the acquisition is simply a strategical determination to physique an endocrinology franchise and expects to adjacent successful Q3 2026.
The woody centers connected 2 endocrine assets Vertex believes could apical $5 billion successful combined highest yearly sales: PALSONIFY, an approved once-daily oral therapy for acromegaly, and atumelnant, a late-stage attraction for congenital adrenal hyperplasia (CAH). Vertex highlighted beardown aboriginal PALSONIFY uptake and payer sum progress.
Vertex plans to concern the acquisition with currency and debt, including $4.5 billion successful committed span financing. Management said the acquisition should person lone a humble near-term fiscal interaction and go accretive to non-GAAP operating income by 2029, portion noting immoderate improvement and information risks stay for atumelnant.

Vertex's Crinetics Deal Balances Growth with Integration Risk

Vertex Pharmaceuticals (NASDAQ:VRTX) said it has entered into a definitive statement to get Crinetics Pharmaceuticals for $85 per stock successful cash, a transaction Vertex executives described arsenic a strategical enlargement into specialty endocrinology.

On a league telephone announcing the deal, Vertex CEO and President Dr. Reshma Kewalramani said the transaction has a full equity worth of astir $10 billion, oregon $8.8 cardinal nett of estimated currency acquired. She said Crinetics brings 2 pb endocrine assets that Vertex believes could make much than $5 cardinal successful combined highest yearly sales: PALSONIFY, an approved oral therapy for acromegaly, and atumelnant, an investigational therapy successful pivotal improvement for congenital adrenal hyperplasia, oregon CAH.

→ Scotiabank Sees a New Growth Story for Cloudflare

CRISPR Therapeutics Gains After Earnings arsenic Pipeline Hope Grows

"Crinetics is an fantabulous strategical acceptable for Vertex," Kewalramani said, citing the company's absorption connected superior diseases, specialty markets, well-understood biology and perchance best-in-class medicines.

PALSONIFY Seen arsenic Blockbuster Opportunity

Kewalramani said PALSONIFY is the archetypal and lone once-daily oral therapy for adults with acromegaly, a uncommon hormonal upset caused by excess maturation hormone. She said the cause was launched successful the U.S. successful October 2025 and was much precocious approved by the European Medicines Agency.

→ PriceSmart Stock Eyes $220 arsenic Chile Expansion Fuels Growth

Read Entire Article